Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges.
J Thorac Oncol
; 19(3): 395-408, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38012985
ABSTRACT
Immune checkpoint inhibitors have become standard-of-care for the treatment of NSCLC; however, their use brings with it the risk of a unique set of inflammatory side effects, termed immune-related adverse events (irAEs). The recognition, diagnosis, and management of irAEs have become essential to clinical practice, with the potential for high-grade toxicities affecting treatment decision-making. This manuscript provides a state-of-the-art review of irAEs as they pertain to patients with NSCLC, by summarizing the common and severe toxicities of the standard immune checkpoint inhibitor regimens and clinical treatment settings relevant to this disease and future directions.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
J Thorac Oncol
Year:
2024
Document type:
Article
Affiliation country:
Irlanda